Great Tree Pharmacy Co., Ltd.

Meeting Agenda to the Annual Shareholders' Meeting 2026

(Summary Translation)

Time: 10 a.m., Friday, May 29, 2026

Venue: 17F, No. 186, Fuxing Rd., Taoyuan Dist., Taoyuan City

Method of convention: Physical shareholders' meeting

I. Calling the Meeting to order (Announcing the total number of shares represented at the Meeting)

II. The Chair's Remarks

III. Report Items

(I) 2025 Business Report.

(II) 2025 Audit Committee’s Audit Report.

(III) 2025 Distribution of Employees’ and Directors’ Remuneration.

(IV) 2025 Appropriation of Net Income in Cash Dividends.

(V) Report on the Handling of Private Placement of Securities by Our Company.

(VI) Report on the Company's Execution of the Third Domestic Unsecured Conversion of Corporate Bonds.

IV. Proposals

(I) 2025 Business Report and Financial Statements.

(II) 2025 Appropriation of Net Income.

V. Discussions

(I) Proposal to Issue New Shares Through Capitalization of Earnings.

(II) Proposal on Private Placement of Common Shares and/or Domestic Unsecured Convertible Corporate Bonds, to Be Handled.

(III) Proposal on the Issuance of Restricted Employee Shares for 2026.

VI. Elections

Proposal on Re-Election of All Directors.

VII. Other Proposals

Proposal to Release the Newly Elected Directors and Their Representatives From Non-Competition Restrictions.

VIII. Extraordinary Motions

IX. Adjournment

Report Items

I. Please examine the Company's 2025 Business Report.

Description: Please refer to the meeting handbook for the Company's 2025 Business Report.

II. Please examine the Company's 2025 Audit Committee's Audit Report.

Description: Please refer to the meeting handbook for the 2025 Audit Committee's Audit Report.

III. Please examine the Company's 2025 Distribution of Employees' and Directors' Remuneration.

Description: In 2025, the profit of the Company was NT$770,462,886, the Directors' remuneration distributed under the Articles of Incorporation was 0.60% of the total amount of NT$4,622,777, and the employees' remuneration was 3% of the total amount of NT$23,113,887. Of the total employee remuneration amount, 93% is allocated for frontline employees' distribution, all of which is paid in cash.

IV. Please examine the Company's 2025 Appropriation of Net Income in Cash Dividends.

Description:

1. Pursuant to Article 23 of the Company's Articles of Incorporation, the Board of Directors is authorized to distribute all or part of the dividends and bonuses in cash and report to the Shareholders' Meeting.
2. The Board of Directors meeting held on February 26, 2026 resolves to distribute cash dividends of NT$473,976,307 for ordinary shares (cash dividends of NT$3.16 per share), and they are to be distributed in cash.
3. Subsequently, if changes occur to the Company's share capital, affecting the number of shares outstanding, leading to adjustments to the rate of shareholders' dividend distribution, the Company proposes to delegate the Chairman with all competent authority to handle related matters. In addition, the Company also proposes to delegate the Chairman to establish related matters, including setting an ex-dividend date.
4. For the current cash dividend distribution, the dividend will be calculated to the amount of one whole NTD, and any decimal point below one NTD will be rounded down. Shares below one NTD will be adjusted from the largest decimal place, until the total amount of cash dividend has been distributed.

V. Report on the Handling of Private Placement of Securities by the Company.

Description:

1. On September 29, 2022, the Company issued its first domestic private placement of unsecured convertible bonds, with a total issuance amount of NT$220,000,000. The bonds matured three years later, on September 29, 2025, and were repaid on October 3, 2025, in accordance with the Regulations.
2. At the Annual Shareholders' Meeting on May 29, 2025, the Company approved a resolution authorizing the Board of Directors to conduct a private placement of common shares and/or domestic unsecured convertible corporate bonds within a limit not exceeding 25 million common shares. According to Article 43-6 of the Securities and Exchange Act, such private placement must be conducted either at once or in installments within one year from the date of the shareholders' resolution. As the May 28, 2026 deadline approaches, due to our inability to secure subscribers, we have been unable to complete the implementation. Therefore, this matter will not be pursued further during the remaining period.

VI. VI. Report on the Company's execution of the third domestic unsecured conversion of corporate bonds.

Description:

1. On February 27, 2025, the Board of Directors passed a resolution to raise NT$1 billion through the third issuance of unsecured convertible corporate bonds for the repayment of bank borrowings and to increase the working capital.
2. For the Company’s third issuance and fundraising of domestic unsecured convertible corporate bonds, please refer to the table below.

Period/Type	The Third Issuance of Domestic Unsecured Convertible Corporate Bonds in 2025
Date of Issuance	July 28, 2025
Expiry Date	July 28, 2028
Total Amount Issued	NT$1,000,000,000
Par Value per Share	The par value is NT$100,000
Duration	Triennial
Coupon Rate	0%
Method of Redemption	Except for the holders of the convertible bonds converted into the Company’s common shares as set out in Article 10 of the Conversion

Period/Type	The Third Issuance of Domestic Unsecured Convertible Corporate Bonds in 2025
	Measures and the early redemption of the bonds by the Company as set out in Article 18 of the Measures or the cancellation of the bonds purchased by the securities dealers business premises, the Company shall repay the bonds held by the bondholders in cash and in one lump sum within ten business days from the day following the maturity of the bonds.
Execution of Fund Application Plans	It has been used to repay bank borrowings and replenish working capital in the fourth quarter of 2025 and has been implemented according to the full use of the capital utilization plan.
Remark	As of March 31, 2026, there have been no requests from bondholders to convert their bonds into common stock.

Proposals

Proposal 1. (proposed by the Board of Directors)

Proposal: Please approve of the Company's 2025 Business Report and Financial Statements.

Description:

1. The Company’s 2025 Financial Statements have been audited by Certified Public Accountants (CPA) Cheng Ching-Piao and Chang Chih-Ming from EY Taiwan and reviewed by the Audit Committee along with the Business Report, and written Audit Report has been issued accordingly.
2. Please refer to the meeting handbook for the 2025 Business Report, CPA Audit Report and the Financial Statements (including Consolidated Financial Statements).

Resolution:

Proposal 2. (proposed by the Board of Directors)

Proposal: Please approve of the Company's 2025 Appropriation of Net Income.

Description:

1. The Company’s net income after tax in 2025 was NT$600,420,754. After adding the undistributed surplus, other comprehensive incomes (the re-evaluation of the defined benefit plan in 2025), and the disposal of equity instruments measured at FVTOCI, and after statutory provisions for legal reserves, the Company’s available distribution surplus was NT$574,557,772, the cash dividend of common shares was NT$473,976,307 (cash dividend of NT$3.16 per share), and common stock dividends amount to NT$89,995,500 (with 60 shares distributed per thousand shares, without compensation).
2. Please refer to the meeting handbook for the Company's 2025 Appropriation of Net Income table.

Discussions

Proposal 1. (proposed by the Board of Directors)

Proposal: Please discuss the proposal to issue new shares through capitalization of earnings.

Description:

1. To meet the operating needs and increase the Company's working capital, the Company intends to transfer NT$89,995,500 to issue 8,999,550 new shares, with a par value of NT$10 per share, all of which are common shares, from the profit available for distribution in 2025.
2. Shareholders' stock dividends are allocated approximately 60 shares per thousand shares according to the proportion of shares held by the shareholders listed in the shareholders' register on the base date of capital increase and allotment. For odd lots of less than one share resulting from this profit increase and capitalization distribution, shareholders may, within five days from the record date for suspension of transfers, piece together to form whole shares through the Company's share transfer agent. Any remaining odd lots after piecing together may be rounded to the nearest dollar (NT$) and paid in cash (to offset fees of book entry of securities on centralized trades and other dematerialized registration fees), with amounts below NT$1 disregarded. The shares shall be authorized for purchase at par value by the Chair from specific individuals.
3. Subsequently, if changes occur to the Company's share capital, affecting the number of shares outstanding, leading to adjustments to the rate of shareholders' dividend distribution, the Company proposes to delegate the Chairman with all competent authority to handle related matters.
4. New shares to be issued in the current capital increase have the same rights and obligations as the common shares already issued.
5. Upon approval from the Shareholders’ Meeting and applying to the competent authority for approval pursuant to legal regulations, the Board of Directors will be authorized to establish the ex-rights date and related matters. In case changes are needed based on competent authority's request for amendment or based on actual needs, the Company proposes to ask the Shareholders' Meeting to delegate the Chairman with all rights to handle related matters.

Resolution:

Proposal 2. (proposed by the Board of Directors)

Proposal: Please discuss the proposal on private placement of common shares and/or domestic convertible corporate bonds.

Description:

1. In order to enrich the working capital to achieve the benefits of expanding the channel, increasing the market share and strengthening the financial structure, the Company intends to propose to the Board of Shareholders to authorize the Board, within the limit of not more than 30 million shares of common shares, depending on the market environment and the Company’s needs, to select one or match the following financing methods at an

appropriate time in accordance with the relevant laws, the Articles of Incorporation of the Company and other competent authorities. If the domestic unsecured convertible corporate bonds are issued through private placement, the number of common shares that can be converted into convertible bonds shall be calculated at the conversion price on the date of private placement within 30 million shares. The Company shall handle them once or in stages, no more than three stages, during a given calendar year since the resolution of the Annual General Shareholders' Meeting, depending on the market and the situation of contacting specific persons. For the basis and rationale for the determination of the private placement price, the method of selecting specific candidates (the applicants have not yet been confirmed), and the necessary reasons for conducting the private placement, please refer to the meeting handbook .

2. For the Regulations Governing the Issuance and Conversion of Private Placement of Unsecured Convertible Corporate Bonds (Tentative), please refer to the meeting handbook.
3. In addition to the actual offering price and the actual conversion price per share, the number of shares issued, the number of shares issued, the actual issuance conditions and conversion methods, the amount of private placement, the capital increase base date, the planned project, the expected progress, the progress of the use of funds, estimated benefits and other outstanding matters, in the future, if amended by the instructions of the competent authority or due to any change in objective environment and market conditions, it is proposed to request the shareholders' ordinary meeting to authorize the Board to dispose of it at its sole discretion.
4. For cooperation in handling the Private Securities, it's planned to hold the 2026 annual shareholders meeting to pass the private placement and to authorize the Chair of the Board or his designated person to negotiate, sign and deliver all contracts or documents related to the issuance of the Private Placement Securities on behalf of the Company and handle all matters necessary for the Company to issue the Private Placement Securities. For all matters not covered above, the Chair of the Board is authorized to handle them by law.

<Supplement> According to the Securities Investors and Futrues Traders Protection Center of Foundation Juridical Person Securities Invetsors and Futrues Traders Protection Center March 25, 2026 Security Guarantee Act Letter No.1150000823, please refet to the meeting handbook

Resolution:

Proposal 3. (proposed by the Board of Directors)
Proposal: Please discuss the proposal on the issuance of restricted employee shares for 2026.

Description:

1. The Company aims to attract and retain outstanding talent, foster a sense of employee cohesion and belonging, increase competitiveness, and maximize benefits for the Company and its shareholders. According to Article 267 of the Company Act and the relevant regulations issued by the Financial Supervisory Commission, including the "Regulations Governing the Offering and Issuance of Securities by Securities Issuers," the issuance of new shares is restricted to employee rights.
2. The details of the proposed issuance of restricted employee shares are as follows:
   (1) Total issuance:
      1) Total amount expected to be issued: Not exceeding 4,000 thousand shares of common stock. The actual number of shares to be issued shall be separately resolved by the Board of Directors after the proposal for issuance of restricted employee shares has been approved by this Annual General Shareholders' Meeting and the competent authority.
      2) Issuance Period: Within two years from the date the effective registration notice from the competent authority is received, the shares may be issued in one or multiple tranches depending on actual needs. The actual issuance date and related matters shall be determined by the Chairman as authorized by the Board of Directors.

   (2) Employee eligibility and allocated shares:
      1) The scope of application is limited to employees of the Company and its domestic and foreign controlled or subordinate companies who have joined the Company on the date of grant of the restricted employee rights new shares. The term "controlled or subordinate company" shall be determined in accordance with Order No. 1070121068 issued by the Financial Supervisory Commission, and the standards set forth in Articles 369-2, 369-3, Paragraph 2 of Article 369-9, and Article 369-11 of the Company Act.
      2) The actual number of shares allocated to eligible employees will be determined based on factors such as seniority, job level, performance evaluation, overall contribution, and special achievements. Such allocation shall be proposed by the Chairman and submitted to the Board of Directors for approval. Employees who also serve as directors or managerial officers of the Company shall first be reviewed by the Remuneration Committee. Employees who do not serve as directors or managerial officers of the Company shall first be approved by the Audit Committee.

3) In accordance with Paragraph 1, Article 56-1 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, the cumulative number of shares subscribable by any single warrant holder under employee stock warrants, plus the cumulative number of restricted employee shares obtained by such person, shall not exceed 0.3% of the total issued shares of the Company. In addition, when combined with the cumulative number of shares subscribable by any single warrant holder under employee share subscription warrants issued pursuant to Paragraph 1, Article 56 of the same Regulations, the total shall not exceed 1% of the total issued shares of the Company.

(3) Issuance terms and conditions:

1) Expected issue price: The issue price of NT$30 per share.

2) Vesting conditions:

①The employee must have remained employed for the period specified below since being granted restricted employee rights shares, without any violation of the company's employment contract or work rules, and whose individual performance evaluations have consistently met the company's individual performance assessment indicators. The vesting percentages are as follows:

Upon completion of one year: 25%	Upon completion of two years: 25%	Upon completion of three years: 25%	Upon completion of four years: 25%

②Individual performance appraisal indicators must be at least "Excellent" (or equivalent) in the performance appraisal grade for the most recent year as of the vesting date, and work results must meet the individual performance standards set by the company, as agreed upon by the company and the individual employee.

3) Type of shares to be issued: New common shares of the Company.

3. Necessity of issuing restricted employee shares awards:

To attract and retain outstanding talent, strengthen the linkage between employee compensation and the Company's financial performance, increase competitiveness, and maximize the common interests of the Company and its shareholders.

4. Potential expense amount, dilution to earnings per share, and other impacts on shareholders' equity:

Based on restricted employee shares not exceeding 4,000 thousand common shares and the average closing price of NT$83.07 per common share during March 2026 (March 1 to

March 31), the total estimated expense amount calculated using a valuation model is NT$212,280,000. After issuance, the expense amounts to be recognized in 2026, 2027, 2028 and 2029 are estimated to be NT$53,070,000, NT$53,070,000, NT$53,070,000, and NT$53,070,000, respectively. The impact on earnings per share is estimated to be approximately NT$0.34, NT$0.34, NT$0.34 and NT$0.34, respectively. As the Company's operations are expected to continue growing in the coming years, the overall assessment indicates that the dilutive effect on future earnings per share will be limited and there will be no material impact on shareholders' equity.

5. Please refet to the meeting handbook for the Company's "Regulations Governing the Issuance of Restricted Employee Shares for 2026".
6. If any amendment or adjustment to the terms herein becomes necessary due to instructions from the competent authority or amendments to relevant laws and regulations, it is proposed that the Annual Shareholders' Meeting authorize the Board of Directors or its authorized representative to handle such matters in full discretion.

Resolution:

Elections

(Proposed by the Board of Directors)

Proposal: Re-election of all Directors.

Description:

1. The fourth term of office is expiring on May 30, 2026, and all Directors of the Company are re-elected at the Annual General Shareholders’ Meeting under the Company Law.
2. In accordance with the provisions of Article 14 of the Articles of Incorporation of the Company, the seven seats (including four seats for Independent Directors) of the elected Directors shall be nominated by the shareholders on the list of candidates for Directors.
3. The term of office of the newly appointed Directors (including Independent Directors) shall be three years, from May 29, 2026, to May 28, 2029. The term of office of the original director shall expire upon the completion of the shareholders’ meeting.
4. The list of candidates for the election of Directors (including Independent Directors) was approved by the 18th Board of Directors of the 4th session of the Company, and please refer to the meeting handbook for their academic experience and other relevant information.
5. Please elect.

Result of election:

Other Proposals

(proposed by the Board of Directors)

Proposal: The case for releasing the newly elected Directors and their representatives from non-competition restrictions, submitted for discussion.

Description:

1. Pursuant to Article 209 (1) of the Company Act, Directors shall explain the important contents of their actions to the shareholders' meeting and obtain their permission for their own or others' conduct that falls within the scope of the Company's business.
2. Considering the newly elected Directors or investment or operation of other companies with the same or similar business scope as the Company and acting as a director, as set out in Article 209 of the Company Act, the 2026 annual shareholders meeting is proposed to agree to lift the restrictions on the competitive behavior of the following Directors and their representatives.

Title	Name	Positions concurrently held in other companies
Juridical Person Directors' Representatives	Representative of Ri-Long Investment Co, Ltd.: Ming-Lung Cheng	Director of Treetop Molecular Biotechnology Co., Ltd. Chairman of Da Yu Property Management Co., Ltd.
Director	Shang-Feng Lu	Chairman of Great Tree Pet Co., Ltd. Director of Enki Biomedical Co., Ltd. Chairman of SUNYAO Healthcare Co., Ltd. Chairman of Senyu Biomedical Co., Ltd. Juridical Person Directors' Representatives of GREAT TREE INTERNATIONAL SDN.BHD.
Juridical Person Directors	Jun Wei Investment Co., Ltd.	None
Independent Director	Tian-Dao Liu	None
Independent Director	Hsing-Wen Wang	None
Independent Director	Min-Hsiung Pan	None
Independent Director	Tsung-Liang Yang	General Manager of Investment Division I ,Top Taiwan Venture Capital Co., Ltd. Representative of Corporate Director, Top Taiwan XV Co., Ltd. Representative of Corporate Director, Taiwan PressPlay Inc. Representative of Corporate Director, Crescendo Lab

Resolution:

Extraordinary Motions

Adjournment